Furthermore, the IL-12 regulon, genes upregulated in anti-CD19 CAR-T cells upon exogenous IL-12 stimulation, was associated with better clinical responses in chronic lymphocytic leukemia (CLL) patients treated with anti-CD19 CAR-T cells. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.